{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:29Z","timestamp":1793892749930,"version":"4.8.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s13760-026-03194-7","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:26:07Z","timestamp":1789385167000},"page":"2113-2119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between cerebrospinal fluid LRRK2 and incident orthostatic hypotension differs by genetic background in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9079-4542","authenticated-orcid":false,"given":"Emadoddin","family":"Kazemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"3194_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna) 124:901\u2013905. https:\/\/doi.org\/10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm (Vienna)"},{"key":"3194_CR2","doi-asserted-by":"publisher","first-page":"1468895","DOI":"10.3389\/fnagi.2025.1468895","volume":"17","author":"H Xu","year":"2025","unstructured":"Xu H, Zheng X, Xing X et al (2025) Advances in autonomic dysfunction research in Parkinson\u2019s disease. Front Aging Neurosci 17:1468895. https:\/\/doi.org\/10.3389\/fnagi.2025.1468895","journal-title":"Front Aging Neurosci"},{"key":"3194_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","volume":"21","author":"R Freeman","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69\u201372. https:\/\/doi.org\/10.1007\/s10286-011-0119-5","journal-title":"Clin Auton Res"},{"key":"3194_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.parkreldis.2011.04.016","volume":"17","author":"DC Velseboer","year":"2011","unstructured":"Velseboer DC, de Haan RJ, Wieling W et al (2011) Prevalence of orthostatic hypotension in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17:724\u2013729. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.04.016","journal-title":"Parkinsonism Relat Disord"},{"key":"3194_CR5","doi-asserted-by":"publisher","first-page":"1612960","DOI":"10.3389\/fnagi.2025.1612960","volume":"17","author":"H Wang","year":"2025","unstructured":"Wang H, Zhang C, Xu D (2025) Orthostatic hypotension in Parkinson\u2019s disease: effects on clinical features and disease severity-a systematic review and meta-analysis. Front Aging Neurosci 17:1612960. https:\/\/doi.org\/10.3389\/fnagi.2025.1612960","journal-title":"Front Aging Neurosci"},{"key":"3194_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/brain\/awae073","volume":"147","author":"MJ Kmiecik","year":"2024","unstructured":"Kmiecik MJ, Micheletti S, Coker D et al (2024) Genetic analysis and natural history of Parkinson\u2019s disease due to the LRRK2 G2019S variant. Brain 147:1996\u20132008. https:\/\/doi.org\/10.1093\/brain\/awae073","journal-title":"Brain"},{"key":"3194_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00415-025-13086-0","volume":"272","author":"W Liu","year":"2025","unstructured":"Liu W, Han Y, Liu Y et al (2025) Impact of LRRK2 and GBA variants on orthostatic hypotension in patients with Parkinson\u2019s disease. J Neurol 272:369. https:\/\/doi.org\/10.1007\/s00415-025-13086-0","journal-title":"J Neurol"},{"key":"3194_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fnins.2020.00526","volume":"14","author":"OS Mabrouk","year":"2020","unstructured":"Mabrouk OS, Chen S, Edwards AL et al (2020) Quantitative measurements of LRRK2 in human cerebrospinal fluid demonstrates increased levels in G2019S patients. Front Neurosci 14:526. https:\/\/doi.org\/10.3389\/fnins.2020.00526","journal-title":"Front Neurosci"},{"key":"3194_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/cts.13541","volume":"16","author":"M Vissers","year":"2023","unstructured":"Vissers M, Troyer MD, Thijssen E et al (2023) A leucine-rich repeat kinase 2 pathway biomarker characterization study in patients with Parkinson\u2019s disease with and without LRRK2 mutations and healthy controls. Clin Transl Sci 16:1408\u20131420. https:\/\/doi.org\/10.1111\/cts.13541","journal-title":"Clin Transl Sci"},{"key":"3194_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41591-026-04262-4","volume":"32","author":"OS Mabrouk","year":"2026","unstructured":"Mabrouk OS, Tichler B, Arnold HM et al (2026) LRRK2-targeting antisense oligonucleotide in Parkinson\u2019s disease: a phase 1 randomized controlled trial. Nat Med 32:1421\u20131431. https:\/\/doi.org\/10.1038\/s41591-026-04262-4","journal-title":"Nat Med"},{"key":"3194_CR11","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/mds.27974","volume":"35","author":"H Iwaki","year":"2020","unstructured":"Iwaki H, Blauwendraat C, Makarious MB et al (2020) Penetrance of Parkinson\u2019s disease in LRRK2 p.G2019S carriers is modified by a polygenic risk score. Mov Disord 35:774\u2013780. https:\/\/doi.org\/10.1002\/mds.27974","journal-title":"Mov Disord"},{"key":"3194_CR12","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1007\/s00415-024-12374-5","volume":"271","author":"CW Chang","year":"2024","unstructured":"Chang CW, Tan CH, Hong WP et al (2024) GBA moderates cognitive reserve\u2019s effect on cognitive function in patients with Parkinson\u2019s disease. J Neurol 271:4392\u20134405. https:\/\/doi.org\/10.1007\/s00415-024-12374-5","journal-title":"J Neurol"},{"key":"3194_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","volume":"45","author":"EM Rocha","year":"2022","unstructured":"Rocha EM, Keeney MT, Di Maio R et al (2022) LRRK2 and idiopathic Parkinson\u2019s disease. Trends Neurosci 45:224\u2013236. https:\/\/doi.org\/10.1016\/j.tins.2021.12.002","journal-title":"Trends Neurosci"},{"key":"3194_CR14","doi-asserted-by":"publisher","first-page":"eaar5429","DOI":"10.1126\/scitranslmed.aar5429","volume":"10","author":"R Di Maio","year":"2018","unstructured":"Di Maio R, Hoffman EK, Rocha EM et al (2018) LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med 10:eaar5429. https:\/\/doi.org\/10.1126\/scitranslmed.aar5429","journal-title":"Sci Transl Med"},{"key":"3194_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mds.28787","volume":"37","author":"J Lake","year":"2022","unstructured":"Lake J, Reed X, Langston RG et al (2022) Coding and noncoding variation in LRRK2 and Parkinson\u2019s disease risk. Mov Disord 37:95\u2013105. https:\/\/doi.org\/10.1002\/mds.28787","journal-title":"Mov Disord"},{"key":"3194_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mds.27989","volume":"35","author":"T Simuni","year":"2020","unstructured":"Simuni T, Brumm MC, Uribe L et al (2020) Clinical and dopamine transporter imaging characteristics of leucine-rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson\u2019s disease participants in the Parkinson\u2019s Progression Markers Initiative: a cross-sectional study. Mov Disord 35:833\u2013844. https:\/\/doi.org\/10.1002\/mds.27989","journal-title":"Mov Disord"},{"key":"3194_CR17","doi-asserted-by":"publisher","first-page":"105626","DOI":"10.1016\/j.nbd.2022.105626","volume":"164","author":"J Horsager","year":"2022","unstructured":"Horsager J, Knudsen K, Sommerauer M (2022) Clinical and imaging evidence of brain-first and body-first Parkinson\u2019s disease. Neurobiol Dis 164:105626. https:\/\/doi.org\/10.1016\/j.nbd.2022.105626","journal-title":"Neurobiol Dis"},{"key":"3194_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41531-024-00730-1","volume":"10","author":"Z Xu","year":"2024","unstructured":"Xu Z, Hu T, Xu C et al (2024) Disease progression in proposed brain-first and body-first Parkinson\u2019s disease subtypes. NPJ Parkinsons Dis 10:111. https:\/\/doi.org\/10.1038\/s41531-024-00730-1","journal-title":"NPJ Parkinsons Dis"},{"key":"3194_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","volume":"130","author":"P Borghammer","year":"2023","unstructured":"Borghammer P (2023) The brain-first vs. body-first model of Parkinson\u2019s disease with comparison to alternative models. J Neural Transm (Vienna) 130:737\u2013753. https:\/\/doi.org\/10.1007\/s00702-023-02633-6","journal-title":"J Neural Transm (Vienna)"},{"key":"3194_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"key":"3194_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1877718X251392799","volume":"16","author":"KB Fraser","year":"2026","unstructured":"Fraser KB, Mirelman A, Mabrouk OS et al (2026) Analysis of \u03b1-synuclein seed amplification assay in carriers of GBA1 and LRRK2 pathogenic variants. J Parkinsons Dis 16:205\u2013216. https:\/\/doi.org\/10.1177\/1877718X251392799","journal-title":"J Parkinsons Dis"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03194-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:51:25Z","timestamp":1793890285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03194-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["3194"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03194-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PPMI study protocol was approved by the institutional review board or independent ethics committee at each participating site and was conducted in accordance with the ethical principles of the Declaration of Helsinki and applicable Good Clinical Practice guidelines. The present study was a secondary analysis of de-identified PPMI data and involved no direct participant contact or new data collection. No additional ethics approval was required for the present analysis.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants in the Parkinson's Progression Markers Initiative provided written informed consent before enrollment.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript contains no identifying individual-level information, images, or videos.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}